Protocols for Monitoring and Managing Long-Term Complications of Bispecific Therapy in Mutlplie Myeloma
Panelists discuss how comprehensive long-term monitoring protocols for patients who have received bispecific therapy typically involve regular follow-ups, standardized testing schedules, and clear communication channels between academic centers and community practices to manage potential complications and adverse events.
Video content above is prompted by the following:
- What protocols and processes do you have in place to continue monitoring and managing potential long-term complications or adverse events associated bispecific therapy (risk of infections, etc)?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
